NCT03319914 (OF-CALISTA) is a clinical trial in Calciphylaxis, sponsored by Hope Pharmaceuticals.

Who is sponsoring NCT03319914?

NCT03319914 is sponsored by Hope Pharmaceuticals.

What condition does NCT03319914 study?

NCT03319914 studies Calciphylaxis.

Is NCT03319914 still recruiting?

NCT03319914 is currently terminated. Last updated 20 November 2018.

Last reviewed 2018-11-20 · How we verify

NCT03319914: OF-CALISTA

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Observational Follow-up to ST-001 Calciphylaxis Pain Treatment With Intravenous Sodium Thiosulfate

Terminated Last updated 20 November 2018

What this trial tests

trial in Calciphylaxis in 5 participants. Terminated before completion.

Timeline

20 October 2017

Primary endpoint
9 November 2018

9 November 2018

Quick facts

Lead sponsor	Hope Pharmaceuticals
Status	Terminated
Study type	OBSERVATIONAL
Enrollment	5
Start date	20 October 2017
Primary completion	9 November 2018
Estimated completion	9 November 2018
Sites	3 locations across United States

Conditions studied

Calciphylaxis — all drugs for Calciphylaxis →

Sponsor

Hope Pharmaceuticals

Who can join

18 and older, any sex, with Calciphylaxis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is an 8-week observational follow-up study of patients who participated in the ST-001 CALISTA study (A Phase 3, Intravenous Sodium Thiosulfate for Acute Calciphylaxis Treatment: A Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial).

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Management of Cutaneous Calciphylaxis.
Kodumudi V, Jeha GM, Mydlo N, Kaye AD. · · 2020 · cited 23× · PMID 32997277 · DOI 10.1007/s12325-020-01504-w

Verify or expand the search:

Other recruiting trials for Calciphylaxis

Currently open trials in the same condition.

NCT04592640 — Human Amniotic-Derived Mesenchymal Stem Cell Therapy for Calciphylaxis · EARLY_PHASE1 · recruiting
NCT06065852 — National Registry of Rare Kidney Diseases · recruiting

Other Hope Pharmaceuticals trials

Trials by the same sponsor.

NCT04401527 — Treatment of Lung Injury From COVID-19 Infection With Intravenous Sodium Nitrite · Phase 2 · withdrawn
NCT03150420 — A Phase 3 Clinical Trial of Intravenous Sodium Thiosulfate in Acute Calciphylaxis Patients · Phase 3 · terminated

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03319914 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Hope Pharmaceuticals
Last refreshed: 20 November 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03319914.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing